Why Is Voydeya So Hard to Find? [Explained for 2026]

If you or someone you care for has been prescribed Voydeya (danicopan) for paroxysmal nocturnal hemoglobinuria (PNH), you may have quickly discovered that getting this medication is nothing like picking up a regular prescription at your corner pharmacy. Voydeya is one of the most access-restricted oral medications in the United States — and for good reasons rooted in safety. This article explains exactly why Voydeya is so hard to find and what steps you can take to get it.

What Is Voydeya and Why Is It So Restricted?

Voydeya (danicopan) is a first-in-class complement Factor D inhibitor approved by the FDA in March 2024 for adults with PNH who experience extravascular hemolysis (EVH) despite treatment with a C5 inhibitor like eculizumab (Soliris) or ravulizumab (Ultomiris). It works by blocking a key step in the alternative complement pathway, stopping the immune system from destroying red blood cells outside blood vessels.

Because Voydeya affects the immune system in a way that dramatically increases the risk of life-threatening infections caused by encapsulated bacteria — including meningitis and pneumonia — the FDA requires it to be distributed under a strict Risk Evaluation and Mitigation Strategy (REMS) program called the VOYDEYA REMS. This program adds layers of requirements that make Voydeya far harder to access than most medications.

The REMS Program: Why You Can't Get It at a Retail Pharmacy

The VOYDEYA REMS program means three things matter before you can get your prescription filled:

Your prescriber must be REMS-certified. Doctors who are not enrolled in the VOYDEYA REMS program cannot legally write a valid prescription for Voydeya. Enrollment requires completing the REMS certification with Alexion.

You must be vaccinated. Before your first dose, you must be vaccinated against Neisseria meningitidis (serogroups A, C, W, Y, and B) and Streptococcus pneumoniae at least 2 weeks in advance, per Advisory Committee on Immunization Practices (ACIP) recommendations.

Only one specialty pharmacy can dispense it. Voydeya is only available through Onco360 specialty pharmacy — not through CVS, Walgreens, Rite Aid, or any other retail pharmacy chain. Onco360 handles the entire dispensing process, including insurance coordination and shipping.

Is There a Voydeya Shortage?

Voydeya is not listed on the FDA's official drug shortage database as of 2026. However, "hard to find" and "in shortage" are not the same thing for this medication. The access challenges come from structural restrictions — REMS requirements, specialty-only dispensing, and mandatory prior authorization from insurance — rather than a manufacturing or supply problem.

That said, many patients report delays of weeks to months before receiving their first supply of Voydeya. These delays are almost always related to insurance prior authorization, REMS enrollment, or vaccine timing requirements — not because a warehouse ran out.

Why Does Insurance Make Voydeya Even Harder to Access?

Voydeya costs approximately $50,000 to $100,000 per year before any savings programs or insurance benefits apply — on top of the cost of the C5 inhibitor it's added to. Because of this, virtually every insurance plan requires prior authorization before coverage begins. Insurance plans frequently require:

Confirmed PNH diagnosis with flow cytometry results

Documentation of ongoing EVH (hemoglobin ≤9.5 g/dL and reticulocyte count ≥120 × 10⁹/L)

Proof of at least 6 months of stable C5 inhibitor therapy prior to adding Voydeya

Evidence of completed required vaccinations (REMS compliance)

First-time prior authorization decisions typically take 5 to 14 business days when submissions are complete. Incomplete paperwork or missing lab results can push the wait to 30 days or longer. Denials are common and often require appeals.

Who Can Prescribe Voydeya?

Only hematologists (and other physicians) who have enrolled in the VOYDEYA REMS program can prescribe Voydeya. This is not something a primary care doctor or urgent care provider can prescribe. If your current hematologist is not yet REMS-certified, they can enroll through Alexion's provider portal — but this takes time.

What Can You Do If You're Struggling to Access Voydeya?

Here are the most effective steps patients can take:

Confirm your prescriber is REMS-certified. Ask your hematologist directly. If not enrolled, ask them to start the enrollment process with Alexion.

Enroll in Alexion OneSource. Call 1-888-765-4747 or visit alexiononesource.com. OneSource case managers can help with prior authorization, vaccine coordination, and financial assistance.

Complete required vaccinations immediately. Don't wait until your PA is approved — getting vaccinated now will remove a barrier and speed up the access timeline.

Work with Onco360 directly. Onco360 is the exclusive dispensing pharmacy for Voydeya. Contact them at 1-888-765-4747 to check on your prescription status and get coordinated support.

Use medfinder to track the process. While Voydeya requires specialty pharmacy dispensing, medfinder can help you verify pharmacy availability and reach out on your behalf when navigating this complex access landscape.

The Bottom Line

Voydeya is hard to find not because of manufacturing shortages, but because of a combination of REMS restrictions, specialty-only dispensing, mandatory prior authorization, and vaccine requirements. The good news is that once the enrollment and insurance hurdles are cleared, Onco360 can typically ship Voydeya reliably to patients across the country. If you're still struggling, explore alternatives to Voydeya and talk to your hematologist about bridging options while access is arranged.

For help locating pharmacies and navigating specialty drug access, visit medfinder.com. You can also read our guide on how to save money on Voydeya for more ways to reduce out-of-pocket costs.